Animal Studies
Hide
Cohorts, endpoints, and approval status for in vivo workflows. Business and scientific purpose: de-risk progression to translational milestones with stronger efficacy, safety, and biomarker evidence. Animal Studies is connected to linked entities, metrics, and workflow actions in this workspace. Use these panels to review evidence, identify risks, and decide the next best scientific action. The view uses deterministic demo data shaped to mirror realistic drug discovery operations.
| id | studyId | cohort | endpoint | approval |
|---|---|---|---|---|
| ANM-001 | ST-001 | Cohort 1 | tumor volume | pending |
| ANM-002 | ST-002 | Cohort 2 | survival | approved |
| ANM-003 | ST-003 | Cohort 3 | biomarker response | approved |
| ANM-004 | ST-004 | Cohort 4 | tumor volume | approved |
| ANM-005 | ST-005 | Cohort 5 | survival | approved |
| ANM-006 | ST-006 | Cohort 6 | biomarker response | pending |
| ANM-007 | ST-007 | Cohort 7 | tumor volume | approved |
| ANM-008 | ST-008 | Cohort 8 | survival | approved |
| ANM-009 | ST-009 | Cohort 1 | biomarker response | approved |
| ANM-010 | ST-010 | Cohort 2 | tumor volume | approved |
| ANM-011 | ST-011 | Cohort 3 | survival | pending |
| ANM-012 | ST-012 | Cohort 4 | biomarker response | approved |
| ANM-013 | ST-013 | Cohort 5 | tumor volume | approved |
| ANM-014 | ST-014 | Cohort 6 | survival | approved |
| ANM-015 | ST-015 | Cohort 7 | biomarker response | approved |
| ANM-016 | ST-016 | Cohort 8 | tumor volume | pending |
| ANM-017 | ST-017 | Cohort 1 | survival | approved |
| ANM-018 | ST-018 | Cohort 2 | biomarker response | approved |
| ANM-019 | ST-019 | Cohort 3 | tumor volume | approved |
| ANM-020 | ST-020 | Cohort 4 | survival | approved |
| ANM-021 | ST-021 | Cohort 5 | biomarker response | pending |
| ANM-022 | ST-022 | Cohort 6 | tumor volume | approved |
| ANM-023 | ST-023 | Cohort 7 | survival | approved |
| ANM-024 | ST-024 | Cohort 8 | biomarker response | approved |
| ANM-025 | ST-025 | Cohort 1 | tumor volume | approved |
| ANM-026 | ST-026 | Cohort 2 | survival | pending |
| ANM-027 | ST-027 | Cohort 3 | biomarker response | approved |
| ANM-028 | ST-028 | Cohort 4 | tumor volume | approved |
| ANM-029 | ST-029 | Cohort 5 | survival | approved |
| ANM-030 | ST-030 | Cohort 6 | biomarker response | approved |
| ANM-031 | ST-031 | Cohort 7 | tumor volume | pending |
| ANM-032 | ST-032 | Cohort 8 | survival | approved |
| ANM-033 | ST-033 | Cohort 1 | biomarker response | approved |
| ANM-034 | ST-034 | Cohort 2 | tumor volume | approved |
| ANM-035 | ST-035 | Cohort 3 | survival | approved |
| ANM-036 | ST-036 | Cohort 4 | biomarker response | pending |
| ANM-037 | ST-037 | Cohort 5 | tumor volume | approved |
| ANM-038 | ST-038 | Cohort 6 | survival | approved |
| ANM-039 | ST-039 | Cohort 7 | biomarker response | approved |
| ANM-040 | ST-040 | Cohort 8 | tumor volume | approved |